NY-CURIA
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is changing its name to Curia, effective July 12, 2021. The new name reinforces the company’s strategic positioning as an end-to-end global CDMO, applying its scientific expertise and extensive capabilities from research and development (R&D) through to commercial manufacturing to enable its pharmaceutical and biotechnology customers to advance important new products that improve lives. Along with the name change, the company is introducing a new brand identity including a new website: CuriaGlobal.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005012/en/
The name Curia is derived from a Latin word for purposeful assembly and references Curia’s patient-inspired mission. The company recently celebrated three decades of growth since its founding in Albany, New York. Today, Curia offers a global suite of R&D and commercial manufacturing capabilities, with industry-leading expertise to help its customers accelerate the journey from idea to impact. Curia employs more than 3,000 people in 21 locations around the world, including more than 600 chemists, 70 biologists, 225 senior scientists and approximately 400 quality and regulatory specialists. The company’s ongoing commitment to science that scales is demonstrated by its 564 active patents and its production of more than 20 treatments included on the list of essential medicines from the World Health Organization.
“Our new name reflects the assembled deep expertise of our people, the breadth of our products, services and solutions, and our relentless determination to help customers advance from curiosity to cure,” said Curia Chairman and CEO John Ratliff. “Our new brand honors our foundation in research and innovation while creating a platform for our ambitions of life-changing science so we can make ever-growing contributions to improving patients’ lives. Over the past three decades we have broadened and deepened our capabilities to become a leading provider of CDMO solutions. Today marks the beginning of the next chapter in our history.”
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005012/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DNIB.com Reports Internet Has 378.5 Million Domain Name Registrations at the End of the Third Quarter of 202523.10.2025 23:00:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the third quarter of 2025 closed with 378.5 million domain name registrations across all top-level domains (TLDs), an increase of 6.8 million domain name registrations, or 1.8% compared to the second quarter of 2025. Domain name registrations also increased by 16.2 million, or 4.5%, year over year. The .com and .net TLDs had a combined total of 171.9 million domain name registrations in the domain name base at the end of third quarter of 2025, an increase of 1.4 million domain name registrations, or 0.8% compared to the second quarter of 2025. The .com and .net TLDs had a combined increase of 2.4 million domain name registrations, or 1.4%, year over year. As of Sept. 30, 2025, the .com domain name base totaled 159.4 million domain name registrations and the .net do
Copeland Expands Industrial Heat Pump Portfolio with Agreement to Acquire SPH Sustainable Process Heat23.10.2025 22:30:00 CEST | Press release
Acquisition enhances Copeland’s industrial heating portfolio Copeland, a global leader in sustainable climate solutions, today announced its agreement to acquire SPH Sustainable Process Heat (SPH), a Germany-based industrial heat pump technology company. This acquisition is expected to expand Copeland’s industrial heating portfolio, allowing the company to deliver a broader range of key heat pump technologies and solutions to new and existing customers. Copeland’s industrial business operates under the brand name Vilter. SPH will continue to operate independently until closing. This acquisition reinforces Copeland’s commitment to enabling the energy transition, in this case, through innovative technologies that enable industrial customers to replace fossil-fuel systems with more energy-efficient heating alternatives. SPH brings a strong technology portfolio, including its innovative ThermBooster™ technology, and demonstrated capability in delivering solutions to a broad range of indust
NIQ Publishes 2025 ESG Progress Report: Advancing Integrity, Innovation, and Impact23.10.2025 22:05:00 CEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2025 Environmental, Social, and Governance (ESG) Progress Report, covering its progress in 2024 and underscoring the company’s commitment to responsible business, data integrity, and inclusive growth across its global operations. “As a leading consumer intelligence company, our responsibility extends far beyond the industries we serve,” said Jim Peck, Executive Chairman and CEO of NIQ. “This year’s ESG Progress Report demonstrates how we are embedding sustainable and inclusive principles into our business, driving value for our clients, investors, associates, and communities.” Key progress areas from 2024Strengthened ESG governance: NIQ formalized its internal ESG governance framework and initiated a Double Materiality Assessment, aligning with the latest global standards and regulations. Advanced data integrity and security: The company advanced its use of AI and machine learning to ensure data quality, priva
Andersen Consulting udvider sine digitale transformationskompetencer med MOYO23.10.2025 19:47:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sine transformationskompetencer inden for teknologi og forretning via en samarbejdsaftale med MOYO, der er et digitalt konsulenthus, som leverer integrerede løsninger inden for strategi, data, teknologi, programmering og talentudvikling. MOYO, der blev grundlagt i 2007 af administrerende direktør Pierre le Roux, kombinerer tjenester inden for rådgivning, teknologi og humankapital-tjenester for at hjælpe en bred kundebase – fra startups til store virksomheder inden for finansielle tjenester, minedrift og detailhandel – med at implementere skalerbare systemer, optimere processer og levere skræddersyede løsninger, der udnytter nye muligheder i den digitale økonomi. "Hos MOYO mener vi, at digital transformation kun lykkes, når løsninger skabes med dyb empati og en klar forståelse for menneskene bag virksomheden," sagde Pierre. "Vores samarbejde med Andersen Consulting afspejler det samme engagement i at skabe meningsfulde, langsigtede forandring
Berry Consultants Releases FACTS 8 Clinical Trial Simulator23.10.2025 19:00:00 CEST | Press release
FACTS 8 introduces support for Ordinal endpoints and a new “Quick Start” feature Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users and new clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023501254/en/ FACTS is the most powerful, flexible, and efficient platform for designing and simulating clinical trials across the full spectrum of drug development — from early Phase I studies to complex, multi-arm platform trials. The new release introduces two major advancements: Full simulation of ordinal endpoints in Phase II and Phase III trial designs, enabling powerful designs with frequentist and Bayesian methods of analysis. A Quick Start feature that streamlines setup for fixed and group sequential trials while maintaining the full simulation power FACTS provide
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom